Cobenfy Launch

Quote
























1. Product shows as discontinued and can't be prescribed by any HCP's
2. Not a single payor win
3. HCP's and patient advocate's up in arms about the pricing
4. Total silence from the ELT on the above

This is a total cluster.
 












anonymous said:
1. Product shows as discontinued and can't be prescribed by any HCP's
2. Not a single payor win
3. HCP's and patient advocate's up in arms about the pricing
4. Total silence from the ELT on the above

This is a total cluster.
Click to expand...
Yes, this will continue for all products. You have no idea how bad it is pre-approval. Medical, Clinical, Regulatory and all teams working pre-approval disrespect all post-approval teams. They all (specifically, medical) have ruined HEOR and any team that works with HEOR, the only team from the payor and pricing side that can work pre-approval. HEOR for the last two years has been treated like scum, downgraded, destroyed and treated as second class citizens. This treatment is for all teams working with them. They are all overloaded, tired and the best of their leadership laid off in 2024. Medical with no real defined role has been creating havoc in all these teams. ELT has done nothing. HR is running away from hiring all things HEOR and payor. 2024 has seen huge layoffs in HEOR and Access teams with the heavy weights out of the game. It will take a decade to build a division that has now been decimated. Even a mild and supportive team like publications was heavily affected when the entire team was laid off. When they realized they laid off too many, HR initiated the worst rehiring process with a few weak laid off individuals rehired who supported Clinical publications and none who would provide payor support. Don’t expect much from the whole payor organization. They are all severely beaten down and pricing is completely unreasonable. All the money is to be made in the US with unreasonable pricing for drugs with not so outstanding efficacy and safety. The rest of the markets are doing great with hiring, retaining jobs and access but are useless to keep the org going. ELT love the docile markets teams and hate all things US.
 












anonymous said:
Yes, this will continue for all products. You have no idea how bad it is pre-approval. Medical, Clinical, Regulatory and all teams working pre-approval disrespect all post-approval teams. They all (specifically, medical) have ruined HEOR and any team that works with HEOR, the only team from the payor and pricing side that can work pre-approval. HEOR for the last two years has been treated like scum, downgraded, destroyed and treated as second class citizens. This treatment is for all teams working with them. They are all overloaded, tired and the best of their leadership laid off in 2024. Medical with no real defined role has been creating havoc in all these teams. ELT has done nothing. HR is running away from hiring all things HEOR and payor. 2024 has seen huge layoffs in HEOR and Access teams with the heavy weights out of the game. It will take a decade to build a division that has now been decimated. Even a mild and supportive team like publications was heavily affected when the entire team was laid off. When they realized they laid off too many, HR initiated the worst rehiring process with a few weak laid off individuals rehired who supported Clinical publications and none who would provide payor support. Don’t expect much from the whole payor organization. They are all severely beaten down and pricing is completely unreasonable. All the money is to be made in the US with unreasonable pricing for drugs with not so outstanding efficacy and safety. The rest of the markets are doing great with hiring, retaining jobs and access but are useless to keep the org going. ELT love the docile markets teams and hate all things US.
Click to expand...
I disagree. The best part of the reorgs was the right-sizing of HEOR. It was bloated.
 






anonymous said:
I disagree. The best part of the reorgs was the right-sizing of HEOR. It was bloated.
Click to expand...
This is an incorrect assessment. You cannot combine HEOR, access, pricing and all other sub teams as one. Some are commercial teams that can only work post approval and others work pre and post approval. Additionally, when the spirit is taken away, there is no productivity. If HEOR was bloated, then many other teams are hugely bloated like medical (the biggest bloat), sales, marketing, clinical and every other team. This is big Pharma. Where do you think people should go? After all you are making all your profits in the US. US must have more jobs. Look at the heavy hiring in the markets and IT dislocation. The other big bloat is in the top positions where not many do real work other than present themselves in nice suits and talk once in a while. They even ask for strategic directions from lower ranks. A deeper assessment is required.
 


































































Top Bottom
Back
Quote